


IASLC



2021 Targeted Therapies of Lung Cancer Meeting

FEBRUARY 17-20, 2021 | WORLDWIDE VIRTUAL EVENT
MARCH 3-4, 2021 | HIGHLIGHTS FOR EUROPE & ASIA

PROGRAM

#TTLC21

CONQUERING THORACIC CANCERS WORLDWIDE

IASLC TTLC 2021 Program

Table of Contents

Program

Day 1 Wednesday, February 17, 2021	3
Day 2 Thursday, February 18, 2021	5
Day 3 Friday, February 19, 2021	9
Day 4 Saturday, February 20, 2021	13

Posters

Posters	17
----------------	-----------

Day 1 | Wednesday, February 17, 2021

15:45 – 16:45 **S01: Early Career/Young Investigator Session**

SIGN UP REQUIRED BY FEBRUARY 15

Chair: Roy Herbst, USA

- 15:45 **S01.01: Welcome Message**
Roy Herbst, USA
- 15:45 **S01.02: Academic Opportunities**
Suresh Ramalingam, USA
- 15:50 **S01.03: Options in Industry**
Leora Horn, USA
- 15:55 **S01.04: FDA and Regulatory Opportunities**
Harpreet Singh, USA
- 16:00 **S01.05: Private-practice Opportunities**
Edward Kim, USA
- 16:05 **S01.06: Basic Science Opportunities**
John Minna, USA
- 16:10 **S01.07: Cancer Therapy Evaluation Program Externship Fellow Program, NCI**
Shakun Malik, USA
- 16:15 **S01.08: Live Discussion in Breakout Rooms with Key Experts**
Lecia Sequist, USA
Peter Ujhazy, Hungary
Luis Raez, USA
Paul A. Bunn, Jr., USA
Neal Ready, USA
Frances Shepherd, Canada

17:00 – 18:00 **S02: Welcome & Opening Keynote**

Chair: Paul A. Bunn, Jr., USA

- 17:00 **S02.01: Opening Remarks**
Paul A. Bunn, Jr., USA, Roy Herbst, USA, Suresh Ramalingam, USA, Lecia Sequist, USA
- 17:10 **S02.05: Cell Free DNA**
Max Diehn, USA
- 17:45 **S02.07: Live Q&A Moderated by Paul A. Bunn, Jr.**

18:10 – 19:10 **IS01: Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC) by Jazz Pharmaceuticals, Inc.**

Chair: Christine Culligan, USA

18:15 **IS01.02: Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC)**
Leo Shunyakov, USA

Day 2 | Thursday, February 18, 2021

13:30 – 14:30 **S03: Targeted Therapies – EGFR**

Chair: Julia Rotow, USA

- 13:30 S03.01: Welcome**
Julia Rotow, USA
- 13:30 S03.02: EGFR Combinations (MET, Chemo, VEGF, Small Cell)**
Helena Yu, USA
- 13:40 S03.03: EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase**
Collin Blakely, USA
- 13:50 S03.04: EGFR Exon 20 Insetions: Novel TKIs, Amivantamab and Other Treatment Options**
Zofia Piotrowska, USA
- 14:00 S03.05: Persister Biology**
Christine Lovly, USA
- 14:10 S03.06: Live Panel Discussion**
Natasha Leigh, Canada (Lead)
Brian Henick, USA
Dara Aisner, USA
Jacquelyne Robichaux, USA
Hatim Husain, USA
Trever Bivona, USA
Balazs Halmos, USA
Heather Wakelee, USA

14:40 – 15:40 S04: Targeted Therapies – ALK & ROS1 Inhibitors

Chair: Viola Zhu, USA

- 14:40 S04.01: Welcome**
Viola Zhu, USA
- 14:40 S04.02: New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib – New Data and Resistance Mechanisms**
Ignatius (Sai-Hong) Ou, USA
- 14:50 S04.03: New Agents Not Yet Approved: Repotectinib, DS6051b**
Jessica Lin, USA
- 15:00 S04.05: Combinations: VEGF, Trametinib, CDK4/6, mTOR**
Shirish Gadgeel, USA
- 15:10 S04.06: Continuing TKI Beyond Progression (All Drivers)**
Ross Camidge, USA
- 15:20 S04.07: Live Panel Discussion**
Thomas Stinchcombe, USA (Lead)
Elaine Shum, USA
Mark Awad, USA
Tejas Patil, USA
Greg Otterson, USA
Sandip Patel, USA
Vincent Lam, USA
Deborah Doroshov, USA

15:50 – 16:50 S05: Targeted Therapies – KRAS

Chair: Sukhmani Padda, USA

- 15:50 S05.01: Welcome**
Sukhmani Padda, USA
- 15:50 S05.02: Sotorasib for KRAS G12C**
Bob Li, USA
- 16:00 S05.03: Adagrasib (MRTX849)**
Lyudmila Bazhenova, USA
- 16:10 S05.04: Effect of Co-Mutations**
John Heymach, USA
- 16:20 S05.05: KRAS G12C Inhibitor Combinations**
Gregory Riely, USA
- 16:30 S05.06: Live Panel Discussion**
David Spiegel, USA (Lead)
Wade Iams, USA
Michael Cheng, USA
Sarah Goldberg, USA
Vamsidhar Velcheti, USA
Adrian Sacher, USA
Ferdinandos Skoulidis, USA
Rajwanth Veluswamy, USA

17:00 – 18:00 S06: Targeted Therapies – All The Others

Chair: Misako Nagasaka, USA

- 17:00 S06.01: Welcome**
Misako Nagasaka, USA
- 17:00 S06.02: MET**
Rebecca Heist, USA
- 17:10 S06.03: RET Fusion-Positive Lung Cancers**
Alex Drilon, USA
- 17:20 S06.04: BRAF**
Ibiayi Dagogo-Jack, USA
- 17:30 S06.05: HER2, NTRK, NRG1 "Too Many Topics for a Pun"**
Stephen Liu, USA
- 17:40 S06.06: Live Panel Discussion**
Karen Kelly, USA (Lead)
Xiuning Le, USA
Matthew Gubens, USA
Fadlo Khuri, Lebanon
Jonathan Riess, USA
Hirva Mamdani, USA
Erin Larkins, USA
Paul Paik, USA

18:10 – 19:10 IS02: New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer by AstraZeneca

Chair: Roy Herbst, USA

- 18:10 IS02.01: Welcome**
Roy Herbst, USA
- 18:15 IS02.02: New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer**
Lecia Sequist, USA

Day 3 | Friday, February 19, 2021

13:30 – 14:30 **S07: Immunotherapy – IO and other Novel Combinations**

Chair: Tina Cascone, USA

- 13:30 S07.01: Welcome**
Tina Cascone, USA
- 13:30 S07.02: Immunotherapy + Multi-kinase Inhibitors**
Joel Neal, USA
- 13:40 S07.03: Immunotherapy Combos: LAG-3, TIM-3, TIGIT, OX-40**
Rachel Sanborn, USA
- 13:50 S07.04: IO + PARPi, VEGFi**
Melissa Johnson, USA
- 14:00 S07.05: Immunotherapy Combinations CTLA-4, 41BB, ICOS**
Jarushka Naidoo, Ireland
- 14:10 S07.06: Live Panel Discussion**
Julie Brahmer, USA (Lead)
Karen Reckamp, USA
Joshua Bauml, USA
John Wrangle, USA
Rosalyn Juergens, Canada
James Welsh, USA
Shadia Jalal, USA
Parneet Cheema, Canada

14:40 – 15:40 S08: Immunotherapy – Biomarkers

Chair: Natalie Vokes, USA

- 14:40 S08.01: Welcome**
Natalie Vokes, USA
- 14:40 S08.02: TMB and Neoantigens**
Matthew Hellmann, USA
- 14:50 S08.03: Statistical Models**
Yu Shyr, USA
- 15:00 S08.04: Multiplexed Tissue Analysis and Tumor Immune Microenvironment**
Kurt Schalper, USA
- 15:10 S08.05: Liquid Biopsy Approaches for Precision Immuno-Oncology**
Valsamo Anagnostou, USA
- 15:20 S08.06: Live Panel Discussion**
Edward Garon, USA (Lead)
Christian Rolfo, USA
Diane Tseng, USA
Dwight Owen, USA
Estelamari Rodriguez, USA
Katerina Politi, USA
David Kozono, USA
Aaron Mansfield, USA

15:50 – 16:50 S09: Immunotherapy – Other Immunologic

Chair: Aaron Lisberg, USA

- 15:50 S09.01: Welcome**
Aaron Lisberg, USA
- 15:50 S09.02: Personalized Cancer Vaccines**
Justin Gainor, USA
- 16:00 S09.03: Cellular Therapies, Adoptive T-cells**
Benjamin Creelan, USA
- 16:10 S09.04: Intratumoral Injections, TILs**
Scott Gettinger, USA
- 16:20 S09.05: Aiming the Immune System at Mutation-driven Tumors**
Charu Aggarwal, USA
- 16:30 S09.06: Live Panel Discussion**
Naiyer Rizvi, USA (Lead)
Kristen Marrone, USA
Kathryn Arbour, USA
Nasser Hanna, USA
Aparna Hegde, USA
Erin Schenk, USA
Kai He, USA
Joshua Reuss, USA

17:00 – 18:00 S10: Antibody Drug Conjugates

Chair: Jose Pacheco, USA**17:00 S10.01: Welcome***Jose Pacheco, USA***17:00 S10.02: Pharmacology and Toxicity of Antibody Drug Conjugates***Alex A. Adjei, USA***17:10 S10.03: ADC for HER 2, HER3 incl Trastuzimab Ematansine and Dexretuxin, DS8021, U31402***Pasi Janne, USA***17:20 S10.04: Trop2 ADCs: IMMU132 & DS-1062***Ben Levy, USA***17:30 S10.05: Other ADCs***Martin Edelman, USA***17:40 S10.06: Live Panel Discussion***Hossein Borghaei, USA (Lead)**Jacob Sands, USA**David Gerber, USA**Conor Steuer, USA**Jennifer Carlisle, USA**Jared Weiss, USA**Liza Villaruz, USA**Ryan Gentzler, USA*

Day 4 | Saturday, February 20, 2021

09:00 – 10:00 S11: Small Cell Lung Cancer

Chair: Christine Hann, USA

- 09:00 S11.01: Welcome**
Christine Hann, USA
- 09:00 S11.02: Chemo-IO in ES-SCLC**
Ticiana Leal, USA
- 09:10 S11.03: SCLC: Emerging Agents (Lurbinectedin, Lipo Irinotecan, APG-1252 [Pelcitoclax])**
Gregory Kalemkerian, USA
- 09:20 S11.04: Emerging Immunotherapy Approaches (AMG 757, GD-2 CAR & Others)**
Taofeek Owonikoko, USA
- 09:30 S11.05: New Therapeutic Targets for SCLC**
Charles Rudin, USA
- 09:40 S11.06: Radiotherapy Issues in SCLC**
Kristin Higgins, USA
- 09:45 S11.07: Live Panel Discussion**
Anne Chiang, USA (Lead)
Victoria Lai, USA
Lauren Byers, USA
Puneeth Iyengar, USA
Benjamin Drapkin, USA
Anne Tsao, USA
Afshin Dowlati, USA
Jonathan Lehman, USA

10:10 – 11:10 S12: Best Fellows Oral Talks

Chair: Corey Langer, USA

- 10:10 S12.01: Welcome**
Corey Langer, USA
- 10:10 S12.02: Neratinib Efficacy in Patients with EGFR Exon 18-Mutant Non-small Cell Lung Cancer (NSCLC): Findings from the SUMMIT Basket Trial**
Amy Cummings, USA
- 10:20 S12.03: Concurrent mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer**
Triparna Sen, USA
- 10:30 S12.04: Beyond Steroids Immunosuppressants in Steroid-refractory Immune Related Adverse Events**
Jia Luo, USA
- 10:40 S12.05: Identifying B7-H6 as a Prospective Immunotherapy Target in Small Cell Lung Cancer**
Portia Thomas, USA
- 10:50 S12.06: Discussant**
Ravi Salgia, USA
- 11:00 S12.07: Live Q&A**

11:20 – 12:20 S13: Stage III/Unresectable

Chair: Narjust Duma, USA

- 11:20 S13.01: Welcome**
Narjust Duma, USA
- 11:20 S13.02: PACIFIC Trials**
Jhanelle Gray, USA
- 11:30 S13.03: Stage III Inoperable NSCLC: Other IO Agents**
Christine Bestvina, USA
- 11:40 S13.04: Ongoing Key Stage III Trials in the NCTN and Beyond**
Nathan Pennell, USA
- 11:50 S13.05: New Innovations in Radiation Therapy for Lung Cancer**
Jeffrey Bradley, USA
- 12:00 S13.06: Live Panel Discussion**
Andrea Bezjak, Canada (Lead)
Henry Park, USA
Jonathan Spicer, Canada
Antoinette Wozniak, USA
Jyoti Patel, USA
Penelope Bradbury, Canada
Angel Qin, USA
Max Diehn, USA

12:30 – 13:30 S14: Therapy for Early Stage

Chair: Sonam Puri, USA

- 12:30 S14.01: Welcome**
Sonam Puri, USA
- 12:30 S14.02: Neoadjuvant Immunotherapy and Chemotherapy Plus Immunotherapy with Adjuvant Immunotherapy: Phase 2 Results and Ongoing Trials**
Patrick Forde, USA
- 12:40 S14.03: Adjuvant Immunotherapy and Chemo-Immunotherapy: Phase 2 Results and Ongoing Trials**
Greg Durm, USA
- 12:50 S14.04: Neoadjuvant and Adjuvant TKI Trials**
Jamie Chaft, USA
- 13:00 S14.05: Pathologic Response Evaluation**
Sanja Dacic, USA
- 13:10 S14.06: Live Panel Discussion**
Neal Ready, USA (Lead)
Jay Lee, USA
Hina Saeed, USA
Jessica Donington, USA
Brendon Stiles, USA
Catherine Shu, USA
Raymond Osarogiagbon, USA
Thomas Marron, USA

13:30 – 14:00 S15: Closing – Faculty Keynote

Chair: Paul A. Bunn, Jr., USA, Roy Herbst, USA, Suresh Ramalingam, USA, Lecia Sequist, USA

- 13:30 S15.01: Introduction Closing Keynote**
Lecia Sequist, USA
- 13:30 S15.02: Academic Publishing: Now and Into the Future**
Alex A. Adjei, USA
- 13:50 S15.03: Live Q&A**
- 14:00 S15.04: Closing Remarks**

Posters

- P01.01: Female Lung Cancer: An Emerging Issue in Bangladesh**
Muhammad Rafiqul Islam, Bangladesh
- P02.01: Increase in Tumour PD-L1 Expression in Non-small Cell Lung Cancer Following Thermal Vapour Ablation is Not Related to Systemic Inflammatory Response**
Kanishka Rangamuwa, Australia
- P03.01: Comparison of Tumor Mutational Burden in Paired Primary Versus Lung Cancer Brain Metastasis**
Matthew Strickland, USA
- P04.01: Non-small Cell Lung Cancer (NSCLC) Comprehensive Genomic Profiling: Integrating Expanded Genomic Sequencing Into the Canadian Publicly Funded Health Care Model**
Kirstin Perdrizet, Canada
- P05.01: Detection of DNA Replication Blocker SLFN11 in Tumor Tissue and Circulating Tumor Cells to Predict Platinum Response in Small Cell Lung Cancer**
Bingnan Zhang, USA
- P06.01: The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC**
Andrew Piper-Vallillo, USA
- P07.01: Sequencing of TKI With or Without Brain Radiotherapy (RT) in EGFR Mutated or ALK Rearranged Non-small Cell Lung Cancer (NSCLC) with Brain Metastases**
Nicholas Giustini, USA
- P07.02: Management of Advanced Non-small Cell Lung Cancer Patients Harboring ROS1 Rearrangement- Experience From a Tertiary Cancer Centre in Eastern India**
Saheli Saha, India
- P08.01: Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors**
Johnathan Ebben, USA
- P09.01: Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions**
Noura Choudhury, USA
- P09.02: Mutated EGFR Pulmonary Adenocarcinoma Experience of the Medical Oncology Department of the Hassan II Hospital University in Fez**
Yassine El Ouai, Morocco
- P09.03: Mechanism of Growth-Inhibitory Effect of Pemetrexed Disodium Heptahydrate on Human PC9 (EGFR Exon 19 Deletion) Cells**
Md Mohiuddin, Japan
- P09.05: EGFR-TKIs Associated Cardiotoxicity in Lung Cancer Patients: An Analysis of FAERS Database**
Dongchen Sun, China

- P09.06: Restoring Therapeutic Efficacy of Osimertinib in EGFR-driven NSCLC by Targeting the BMP/Endoglin Signaling Axis**
Manish Thiruvalluvan, USA
- P10.01: The Frequency of KRAS Mutations in Brazilian Lung Cancer Patients**
Rodrigo De Oliveira Cavagna, Brazil
- P10.02: Inhibitory Effect of Pemetrexed Disodium Heptahydrate on the Growth of KRAS-Dependent A549 Lung Cancer Cells**
Md Mohiuddin, Japan
- P11.01: Correlation Between Histological Subtypes and Prognosis in Patients With Early Stage Lung Adenocarcinoma: An Observational Retrospective Cohort Study**
Stylianos Gaitanakis, Greece
- P11.02: Expressions of Biomarkers of Malignant Pleural Mesothelioma at Pham Ngoc Thach Hospital, Vietnam in 5 Years From 2015-2019**
Nguyen Son Lam, Viet Nam